Vimseltinib

CSF1R inhibition has no established intrinsic nephrotoxic mechanism — the tubular and glomerular epithelium are not primary CSF1R-dependent compartments, and there is no VEGF, calcineurin, platinum, or immune-checkpoint pathway engaged that would predict ATN, TMA, AIN, or podocytopathy. The relevant kidney consideration is indirect and largely artifactual: (1) marked CPK elevation (a class effect of CSF1R inhibition, reflecting altered macrophage handling of muscle CK rather than true rhabdomyolysis in most cases) can confound muscle/renal lab interpretation; (2) peripheral and periorbital edema with fluid shifts may transiently alter volume status and creatinine; and (3) any creatinine rise is best regarded as pseudo-AKI or hemodynamic/prerenal rather than structural until proven otherwise. Class read-across from pexidartinib (the other approved CSF1R inhibitor for TGCT) similarly shows hepatic — not renal — as the organ of concern (PMID 33197285).

Typically no renal manifestation. When laboratory abnormalities arise, expect asymptomatic CPK elevation (often the most prominent grade 3/4 lab finding) and peripheral/periorbital edema. A modest, often reversible serum creatinine fluctuation may accompany edema or volume shifts but is generally not associated with structural kidney injury, active urinary sediment, or proteinuria. Frank AKI, nephrotic-range proteinuria, hematuria, or electrolyte-wasting syndromes are not characteristic and should prompt a search for an alternative cause.

For an isolated creatinine rise, assess volume status and reversible hemodynamic contributors first; correct volume depletion and hold/adjust concurrent diuretics or RAAS agents as appropriate. Check CPK and a urinalysis — bland sediment without proteinuria supports a pseudo-AKI/prerenal pattern rather than intrinsic injury. Manage CPK elevations and edema per the Romvimza label dose-modification scheme (dose interruption/reduction for significant or symptomatic elevations). Refer to nephrology and reconsider the diagnosis if there is true AKI, active sediment, new proteinuria, or features of TMA, none of which are expected from CSF1R inhibition. Avoid attributing structural kidney disease to the drug without supporting evidence.Lesion-level management framework

No dedicated renal dose-adjustment requirement is established for clinically meaningful direct nephrotoxicity, as the drug is not a recognized nephrotoxin. Vimseltinib is given orally 30 mg twice weekly in 28-day cycles. Formal pharmacokinetic data in moderate-to-severe renal impairment and in dialysis patients are limited; prescribe with standard caution in advanced CKD and consult the current label for any renal/hepatic dosing language, since hepatic handling and CYP interactions are the more pertinent PK considerations for this agent.

Not characterized. As a small-molecule kinase inhibitor that is highly protein-bound and predominantly hepatically metabolized, vimseltinib is unlikely to be meaningfully removed by hemodialysis, but no formal dialyzability data are available; do not assume dialysis clearance.

A creatinine rise on vimseltinib should be worked up as pseudo-AKI/prerenal before structural injury is invoked. Distinguish from: (1) volume depletion/diuretic effect from edema management (prerenal — urine concentrated, bland sediment); (2) CPK-driven lab confounding versus true rhabdomyolysis-related AKI (check CPK trend, urine myoglobin); (3) unrelated intrinsic causes such as ATN from intercurrent illness, AIN from concomitant drugs (PPIs, antibiotics), or contrast exposure; and (4) for any TMA, proteinuria, or hypertension picture, look for an alternative agent (e.g., concurrent VEGF-pathway or platinum therapy), as these are not features of CSF1R inhibition.